31 August 2020 1 Min Read
Nestlé to buy rest of stake in Aimmune Therapeutics
Aimmune's Palforzia peanut allergy treatment, which recently gained US approval for children, has sales potential of $1bn
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In